Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Irritable Bowel Syndrome (IBS) Clinical Trials

A listing of Irritable Bowel Syndrome (IBS) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (77) clinical trials

Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age With Irritable Bowel Syndrome With Constipation (IBS-C)

The purpose of this study is to evaluate the safety, efficacy and pharmacokinetic (PK) parameters of plecanatide of once daily oral 3 dose levels of plecanatide (0.5, 1.0, or 1.5 mg) for 4 weeks as treatment in children 6 to <18 years of age with IBS-C. The study will include ...

Phase

A Trial for New Treatment of Adult Patients With Irritable Bowel Syndrome

500 subjects will be enrolled with a diagnosis of IBS as defined by Rome IV criteria will be classified into cohorts according to the Rome IV classification of IBS subtypes. Each cohort (Cohort C & Cohort D) will recruit 250 subjects who will randomly receive either Blautix or matching placebo ...

Phase

Neurotrophic Factors Tight Junction Proteins and Cytokines in IBS

To evaluate the role of neurotrophic factors (NGF, GDNF, TRPV-1), to quantity tight junction proteins (ZO-1, occludin, claudin) and cytokines (IL-8, TNF-a, IL-1b) in the colonic mucosa of IBS patients and also clarify sex differences in the pathophysiology of IBS.

Phase N/A

Effect of Curcumin on Gut Microbiota in IBS

This is a prospective, placebo-controlled, double blinded, randomized control trial. This study will evaluate the effect of curcumin food supplement on gut microbiota of children with irritable bowel syndrome. Curcumin is a commonly used spice in Asian cooking and has a very good safety profile. Developing preparation of this compound ...

Phase N/A

Fecal Microbiota Transplantation for Irritable Bowel Syndrome

The present clinical trial aims to re-establish a gut functionality state of intestinal flora through FMT as a therapy for Irritable bowel syndrome(IBS). We established a standard microbiota isolation from donated fresh stool in lab. Then the microbiota is transplanted to the whole colon through a tube. Patients from Guangzhou ...

Phase

An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis [EXPEDITION]

The present study (3151-201-008) seeks to evaluate the efficacy and safety of brazikumab versus placebo in patients with moderately to severely active UC and will include assessments of clinical responses as demonstrated by improvement of symptoms and of colonic mucosal appearance as observed on endoscopy.

Phase

Multiple Dose Ethnobridging PK Study in Healthy Subjects

A Phase 1, double blind, placebo controlled, 4 cohort, multiple dose study in healthy adult Japanese and Caucasian subjects.

Phase

Mediterranean Diet and the Gut Microbiome

Irritable bowel syndrome (IBS) is the most prevalent and well-studied functional gastrointestinal disorder. While IBS has no direct mortality, it does compromise quality of life, incurs morbidity, and has a substantial economic impact on society. The gut microbiome may play a significant role in the pathogenesis of IBS. Even though ...

Phase N/A

A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a highly prevalent but poorly understood condition with limited treatment options. Recent evidence has established small intestinal bacterial overgrowth (SIBO) and alterations in fecal microbiota as potential etiologies in the pathogenesis of IBS-D. Current therapies, including a nonabsorbable antibiotic rifaximin or diet low in ...

Phase

Rifamycin SV-MMX 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D

The objective of this study is to evaluate the safety and efficacy Rifamycin SV-MMX 600 mg tablets for patients with diarrhoea-predominant irritable bowel syndrome when administered two to three times daily.

Phase